Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kipres Generics Might Add Bronchial Asthma Indication before December Listing
October 21, 2016
- Janssen Files Anti-IL-6 Antibody Sirukumab for RA
October 21, 2016
- Humira Biosimilar Hits Primary Endpoint in Global PIII: Fujifilm, Kyowa Kirin
October 20, 2016
- Kaketsuken’s Biz Transfer Talks Fall Apart, but Minister Nixes Its Continued Operations
October 20, 2016
- Astellas Calls Off Biz Transfer Talks with Kaketsuken
October 19, 2016
- UK’s Clinigen Launches Japan Operations with Takeover of Foscavir
October 19, 2016
- Kaketsuken Denies Unauthorized Manufacturing or Cover-up, Blames Ambiguity in Approval Doc
October 19, 2016
- Entyvio’s Real-World Data Support Trial Results: Takeda
October 18, 2016
- Ethical Drug Sales Up 2.7% in August: Crecon Report
October 18, 2016
- JT Grants S. Korea Rights for Anemia Drug to JW Pharmaceutical
October 17, 2016
- PDUFA Date for COPD Drug Set for May 29, 2017: Sunovion
October 17, 2016
- Sandoz Will Outpace Generic Market Growth: New Japan Chief
October 14, 2016
- Gilead Japan Trying to Dig Up Untreated Hep C Patients as Demand Ebbs
October 14, 2016
- Mark Tennyson to Take Helm of Amgen Astellas BioPharma
October 14, 2016
- Daiichi Sankyo, Dana-Farber Link Up on Lung Cancer Preclinical Research
October 14, 2016
- Gilead Japan Eyes Cancer, Inflammatory Disease Meds to Raise Profile as Specialty Pharma
October 13, 2016
- Patient Enrollment for Tepotinib PII Begins in Japan: Merck Serono
October 13, 2016
- 69.2% Response Rate Seen in Lenvatinib, Pembrolizumab Combination: Eisai
October 13, 2016
- Daiichi Sankyo Kicks Off Quizartinib Global PIII for 1st-Line AML
October 13, 2016
- Takeda to Tighten R&D Focus, Strengthen Collaboration with Outside Parties; Main Challenge Will Be Financial
October 13, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…